

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement appears for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of Extrawell and/or securities of United Gene.



**EXTRAWELL PHARMACEUTICAL
HOLDINGS LIMITED**

精優藥業控股有限公司*

(Incorporated in Bermuda with limited liability)

(Stock Code: 858)



**UNITED GENE HIGH-TECH
GROUP LIMITED**

聯合基因科技集團有限公司

*(Incorporated in the Cayman Islands and
continued in Bermuda with limited liability)*

(Stock Code: 399)

**JOINT ANNOUNCEMENT REGARDING
EXTENSION OF LONG STOP DATE IN RELATION TO**

**MAJOR AND CONNECTED
TRANSACTION CONCERNING
THE DISPOSAL OF
51% SHAREHOLDING INTEREST
IN SMART ASCENT LIMITED**

**(1) MAJOR TRANSACTION;
(2) PROPOSED ISSUANCE OF
CONVERTIBLE BONDS UNDER
THE SPECIFIC MANDATE; AND
(3) CONTINUING CONNECTED
TRANSACTION CONCERNING
THE ACQUISITION OF
51% SHAREHOLDING INTEREST
IN SMART ASCENT LIMITED**

Reference is made to the joint announcements of United Gene High-Tech Group Limited (“**United Gene**”) and Extrawell Pharmaceutical Holdings Limited (“**Extrawell**”) dated 18 March 2014 and 19 March 2014 (the “**Announcements**”) in relation to, among others, the Acquisition/Disposal (as defined in the Announcements) and the circular of United Gene dated 26 June 2014 and the circular of Extrawell dated 27 June 2014 (the “**Circulars**”) and the announcements of United Gene dated 23 April 2014, 16 May 2014, 30 May 2014, 12 June

* *For identification purpose only*

2014 and 25 June 2014 and the announcements of Extrawell dated 30 April 2014, 14 May 2014, 30 May 2014, 12 June 2014 and 25 June 2014 in relation to the delay in despatch of the Circulars (the “**Delay Announcements**”) and the announcement of Extrawell dated 15 July 2014 and the announcement of United Gene dated 16 July 2014 relating to the poll results of their respective special general meetings (the “**Poll Results Announcements**”).

Capitalized terms used herein shall have the same meanings as those defined in the Announcements, the Circulars, the Delay Announcements and the Poll Results Announcements unless defined otherwise.

THE CONFIRMATION LETTER

As disclosed in the Announcements and the Circulars, Completion is conditional upon, among other things, the fulfillment of certain conditions precedent on or before Long Stop Date, being 18 July 2014 or such other date as the Vendor and the Purchaser may agree in writing.

As additional time is required for the fulfillment of the relevant conditions precedent, on 17 July 2014 (after trading hours), the Vendor and the Purchaser executed a confirmation letter to the Acquisition Agreement (the “**Confirmation Letter**”), pursuant to which the Vendor and the Purchaser agreed to extend Long Stop Date to 31 July 2014 or such other date as the Vendor and the Purchaser may agree in writing.

Save and except for the above, all other terms and conditions of the Acquisition Agreement shall remain unchanged and continue in full force and effect.

Completion of the Acquisition/Disposal is subject to fulfillment of the conditions precedent as set out in the section headed “Conditions Precedent” in the Announcements. As the Acquisition/Disposal may or may not proceed, shareholders and potential investors of United Gene and Extrawell are advised to exercise caution when dealing in securities of United Gene and Extrawell, and if they are in any doubt about their position, they should consult their professional advisers.

By Order of the Board
Extrawell Pharmaceutical Holdings Limited
Xie Yi
Chairman

By Order of the Board
United Gene High-Tech Group Limited
Lee Nga Yan
Executive Director

Hong Kong, 17 July 2014

As at the date of this announcement, the board of directors of United Gene comprises Ms. Jiang Nian (chairman & non-executive director), Ms. Lee Nga Yan (executive director), Dr. Guo Yi (executive director), Ms. Xiao Yan (non-executive director), Ms. Wu Yanmin (non-executive director), Ms. Chen Weijun (independent non-executive director), Dr. Zhang Zhihong (independent non-executive director) and Mr. Wang Rongliang (independent non-executive director).

As at the date of this announcement, the board of directors of Extrawell comprises executive directors as Dr. Xie Yi, Dr. Lou Yi, Mr. Cheng Yong, Ms. Wong Sau Kuen and Mr. Liu Kwok Wah and independent non-executive directors as Mr. Fang Lin Hu, Mr. Xue Jing Lun and Ms. Jin Song.